免疫調(diào)節(jié)劑對家兔皮膚結(jié)核模型液化進(jìn)程及結(jié)核菌載量的影響
發(fā)布時(shí)間：2018-08-20 12:34
【摘要】：目的：評價(jià)免疫調(diào)節(jié)劑重組人干擾素-γ(rIFN-γ)、重組人白細(xì)胞介素-2(rIL-2)、地塞米松及環(huán)磷酰胺(CTX)分別對家兔皮膚結(jié)核結(jié)節(jié)形成發(fā)展過程(特別是結(jié)節(jié)液化發(fā)生、發(fā)展過程)及液化物質(zhì)中結(jié)核菌載量的影響,初步建立家兔皮膚結(jié)核液化模型藥物評價(jià)方法,從而為結(jié)核病灶液化及空洞形成發(fā)展機(jī)制的研究及相關(guān)治療藥物的評價(jià)提供研究思路及方法。方法：隨機(jī)將家兔分為六組,即rIFN-γ組、rIL-2組、高劑量地塞米松(DH)組、低劑量地塞米松(DL)組、CTX組及生理鹽水對照組。各組分別以一定劑量和用法對健康家兔給予干預(yù)。免疫調(diào)節(jié)劑干預(yù)第17天,用5×106CFU的牛分枝桿菌減毒株BCG對家兔腹背部進(jìn)行皮內(nèi)注射,建立家兔皮膚結(jié)核模型。在其后的持續(xù)干預(yù)過程中,動態(tài)觀察各組家兔皮膚結(jié)核結(jié)節(jié)形成發(fā)展過程,記錄結(jié)節(jié)肉芽腫、液化、破潰、愈合的時(shí)間和各時(shí)期結(jié)節(jié)的形態(tài)和大小,并觀察特定時(shí)期各組家兔皮膚結(jié)節(jié)的病理形態(tài)；計(jì)數(shù)各組家兔皮膚結(jié)核結(jié)節(jié)液化高峰期的液化物質(zhì)中的結(jié)核菌載量;ELISA法檢測各組家兔血清中細(xì)胞因子IFN-γ、IL-2.IL-4.IL-17分泌水平；綜合分析細(xì)胞因子水平對結(jié)核結(jié)節(jié)形成發(fā)展的影響及細(xì)胞因子水平與結(jié)核結(jié)節(jié)液化物質(zhì)中結(jié)核菌載量的關(guān)系。 結(jié)果： 1.各組家兔皮膚結(jié)核結(jié)節(jié)的發(fā)展變化有差異,具體表現(xiàn)為：各組家兔結(jié)核結(jié)節(jié)發(fā)展的各時(shí)期(肉芽腫、液化,破潰,愈合)時(shí)間不同,各組在各時(shí)期的結(jié)核結(jié)節(jié)體積大小不同： rIL-2組家兔皮肽結(jié)核結(jié)節(jié)的液化進(jìn)程最快,在BCG接種后第8天即開始液化,破潰最早,在BCG接種后第11天結(jié)節(jié)發(fā)生破潰,并出現(xiàn)兩次液化高峰,BCG接種后第13天即達(dá)到第一次液化高峰。液化時(shí)結(jié)節(jié)體積在各組中最大,第一次液化高峰時(shí)達(dá)到3289±354mm3,明顯大于對照組結(jié)節(jié)體積2563±17mm3(P0.05)。結(jié)節(jié)消退速度快,愈合開始時(shí)間最早,在BCG接種后第17天便開始第一次液化后的愈合。rIFN-γ組的結(jié)核結(jié)節(jié)各時(shí)期發(fā)生時(shí)間和結(jié)節(jié)體積僅次于rIL-2組,也出現(xiàn)兩次液化高峰。 環(huán)磷酰胺組(CTX)結(jié)核結(jié)節(jié)各時(shí)期的發(fā)生時(shí)間與對照組無差異,結(jié)節(jié)體積小于對照組。低劑量地塞米松(DL)組的皮膚結(jié)核結(jié)節(jié)體積最小,肉芽腫時(shí)期最大體積為751±153mm3,顯著小于對照組結(jié)節(jié)體積1699±149mm3(P0.05)。液化高峰時(shí)結(jié)節(jié)體積(601±297mm3)也顯著小于對照組(2563±17mm3)(P)0.05),且液化過程不明顯。高劑量地塞米松(DH)組未形成明顯的肉芽腫結(jié)節(jié),且未觀察到液化現(xiàn)象。 2.各組家兔皮膚結(jié)核結(jié)節(jié)液化高峰期液化物質(zhì)中的結(jié)核菌載量不同： rIL-2組結(jié)核菌載量為各組中最低,第一次液化高峰時(shí)結(jié)核菌載量為3.0×106CFU/g,顯著低于對照組結(jié)核菌載量(6.9x106CFU/g),第二次液化高峰時(shí)結(jié)核菌載量(1.7×105CFU/g)顯著低于第一次液化高峰時(shí)的載量。低劑量地塞米松(DL)組結(jié)核菌載量(2.8×107CFU/g)顯著高于對照組,為各組中最高。 3.各組家兔皮膚結(jié)核結(jié)節(jié)發(fā)展變化的不同時(shí)期內(nèi)血清細(xì)胞因子IFN-γ、IL-2、IL-4、IL-17的分泌水平不同： γIFN-γ組在肉芽腫期的血清IFN-γ水平(1706.3±104.3pg/ml)和液化高峰期的水平(2662.9±208.5pg/ml)均顯著增高,高于給藥前水平(866.2±29pg/ml),且液化高峰期水平(2662.9±208.5pg/ml)高于對照組液化高峰期的水平(964.9±51.7pg/m1)。 rIL-2組和rIFN-γ組的血清IL-2水平在肉芽腫期(rIL-2組：289.1±14.5pg/ml；rIFN-γ組：211.1±17.6pg/m1)、液化高峰期(rIL-2組：318±25.7pg/ml;rIFN-γ組：297.9±23.2pg/m1)和愈合期(rIL-2組：205.7±9.9pg/ml;rIFN-γ組：231.6±19.8pg/m1)均顯著增高,高于各組給藥前水平(rIL-2組：103.5±3.9pg/ml;rIFN-γ組：79.2±2.0pg/ml),且液化高峰期的水平最高(rIL-2組：318±25.7pg/ml;rIFN-γ組：297.9±23.2pg/ml),均高于對照組液化高峰期的水平(201±5.9pg/m1)。 對照組的IL-4水平在液化高峰期(91.2±10.1pg/m1)和愈合期(87.7±3.1pg/ml)增高,顯著高于給藥前水平(50.6±0.5pg/ml)。 各組的血清IL-17水平在液化高峰期時(shí)均增高,其中rIFN-γ組在液化高峰期時(shí)的IL-17水平(130.1±9.6pg/ml)顯著高于給藥前水平(54.4±2.3pg/ml)。 4.細(xì)胞因子水平與結(jié)核結(jié)節(jié)大小及細(xì)胞因子水平與結(jié)核結(jié)節(jié)液化物質(zhì)中細(xì)菌載量的相關(guān)性分析顯示血清IL-2水平與結(jié)核結(jié)節(jié)大小呈正相關(guān)(r2=0.748,P=0.058),與液化高峰期液化物質(zhì)中結(jié)核菌載量呈反相關(guān)(r2=0.875,P=0.020)。 結(jié)論： 1.不同免疫調(diào)節(jié)劑對結(jié)核結(jié)節(jié)形成發(fā)展過程(特別是結(jié)節(jié)液化發(fā)生、發(fā)展過程)產(chǎn)生不同影響,對病灶內(nèi)結(jié)核菌的存活也產(chǎn)生不同影響。 2.白細(xì)胞介素-2顯著促進(jìn)結(jié)核病灶液化的發(fā)生和發(fā)展,并促進(jìn)結(jié)核病灶內(nèi)結(jié)核菌載量的下降。地塞米松抑制結(jié)核病灶液化的發(fā)生和發(fā)展,并有利于結(jié)核菌在病灶中的存活。 3.初步建立了家兔皮膚結(jié)核液化模型藥物評價(jià)方法。
[Abstract]:AIM: To evaluate the effects of recombinant human interferon-gamma (rIFN-gamma), recombinant human interleukin-2 (rIL-2), dexamethasone and cyclophosphamide (CTX) on the formation and development of tuberculous nodules (especially the occurrence and development of tuberculous nodules) in rabbit skin and the load of tuberculous bacteria in the liquefied substances, respectively. Methods: Rabbits were randomly divided into six groups: rIFN-gamma group, rIL-2 group, high-dose dexamethasone (DH) group, low-dose dexamethasone (DL) group, CTX group and normal saline control group. On the seventeenth day after the intervention of immunomodulators, the rabbit skin tuberculosis model was established by intradermal injection of 5 *106 CFU attenuated Mycobacterium bovis strain BCG into the abdomen and back of rabbits. The formation and development of skin tuberculosis nodules were observed dynamically during the continuous intervention. The morphology and size of granuloma, liquefaction, ulceration, healing time and nodules in each period were recorded, and the pathological morphology of skin nodules in each group was observed; the tuberculosis bacterial load in the liquefied substances of skin tuberculosis nodules in each group was counted; the serum cytokines IFN-gamma, IL-2.IL-4 in each group were detected by ELISA. IL-17 secretion level; comprehensive analysis of cytokine level on tuberculosis nodule formation and development and cytokine level and tuberculosis nodule liquefaction substance in the relationship between tuberculosis bacterial load.
Result:
1. The development and change of tuberculous nodules in skin of rabbits in each group are different. The specific manifestations are as follows: the development time of tuberculous nodules in each group is different (granuloma, liquefaction, ulceration, healing), and the volume and size of tuberculous nodules in each group are different in each period:
In the rIL-2 group, the nodules began to liquefy at the 8th day after BCG inoculation. The nodules began to liquefy at the earliest time. On the 11th day after BCG inoculation, the nodules broke and had two peaks of liquefaction. On the 13th day after BCG inoculation, the nodules reached the first liquefaction peak. The nodule volume in rIFN-gamma group was significantly larger than that in rIL-2 group (P 0.05).
The tuberculous nodule volume of low dose dexamethasone (DL) group was the smallest, and that of granuloma group was 751 (+ 153mm3), which was significantly smaller than that of control group (1699 (+ 149mm3) (P 0.05). The nodule volume of low dose dexamethasone (DL) group was (601 < 297) at liquefaction peak. Mm3 was also significantly lower than that of control group (2563
2. in the peak period of liquefaction of skin tuberculous nodules in different groups of rabbits, the amount of Mycobacterium tuberculosis in liquefied substances varied.
The load of tuberculosis bacteria in rIL-2 group was the lowest in each group. At the first liquefaction peak, the load of tuberculosis bacteria was 3.0 *106 CFU/g, which was significantly lower than that in control group (6.9x106 CFU/g). At the second liquefaction peak, the load of tuberculosis bacteria (1.7 *105CFU/g) was significantly lower than that at the first liquefaction peak. 07CFU/g) was significantly higher than that in the control group, the highest among all groups.
3. The levels of serum cytokines IFN-gamma, IL-2, IL-4 and IL-17 were different in different stages of tuberculous nodule development in each group.
The levels of serum IFN-gamma in granulomatous stage (1706.3+104.3 pg/ml) and peak liquefaction stage (2662.9+208.5 pg/ml) in gamma-IFN-gamma group were significantly higher than those before administration (866.2+29 pg/ml), and the peak liquefaction stage (2662.9+208.5 pg/ml) was higher than that in control group (964.9+51.7 pg/ml).
Serum levels of IL-2 in rIL-2 group and rIFN-2 group and rIFN-gamma group were at granuloma stage (rIL-2 group: 289.1 + 14.5 pg / ml; rIFN-gamma group: 211.1 + 17.6 pg / ml 1), liquefaction peak (rIL-2 group: 318 + 25.7 pg / ml; rIFN-gamgroup: 297.9 + 23.2 pg / m1) and healstage (rIL-2 group: 205.7 + 9.7 + 9.9.9 9 9 pg / ml; rIFN-gamgroup: 211.1 1 1 1 + 17.1 + 17.6 pg / ml), liquliquliquefpeak (rIL-2 group: 318 + 25.8 + 25.7 7 7.7 It was significantly higher than that of the water before administration in each group. The levels of serum levels in rIL-2 group (103.5+3.9 pg/ml) and rIFN-gamma group (79.2+2.0 pg/ml) were the highest (318+25.7 pg/ml in rIL-2 group and 297.9+23.2 pg/ml in rIFN-gamma group), which were higher than those in control group (201+5.9 pg/m1).
The level of IL-4 in the control group was significantly higher at the peak liquefaction stage (91.2+10.1 pg/m1) and the healing stage (87.7+3.1 pg/ml) than that before administration (50.6+0.5 pg/ml).
The serum levels of IL-17 in each group increased during the peak period of liquefaction, and the levels of IL-17 in rIFN-gamma group at the peak period of liquefaction (130.1+9.6 pg/ml) were significantly higher than those before administration (54.4+2.3 pg/ml).
4. Correlation analysis of cytokine level with tuberculosis nodule size and cytokine level with tuberculosis nodule liquefaction substance bacterial load showed that serum IL-2 level was positively correlated with tuberculosis nodule size (r2 = 0.748, P = 0.058), and was inversely correlated with tuberculosis bacterial load in liquefaction substance during liquefaction peak (r2 = 0.875, P = 0.020).
Conclusion:
1. Different immunomodulators have different effects on the formation and development of tuberculosis nodules, especially on the liquefaction and development of tuberculosis nodules, and on the survival of tuberculosis bacteria in the nodules.
2. Interleukin-2 significantly promotes the occurrence and development of tuberculosis lesion liquefaction, and promotes the decrease of tuberculosis bacteria load in the lesion. Dexamethasone inhibits the occurrence and development of tuberculosis lesion liquefaction, and is conducive to the survival of tuberculosis bacteria in the lesion.
3. a preliminary evaluation method for rabbit skin tuberculosis liquefaction model was established.
【學(xué)位授予單位】：蘭州大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2012
【分類號】：R392
本文編號：2193625
[Abstract]:AIM: To evaluate the effects of recombinant human interferon-gamma (rIFN-gamma), recombinant human interleukin-2 (rIL-2), dexamethasone and cyclophosphamide (CTX) on the formation and development of tuberculous nodules (especially the occurrence and development of tuberculous nodules) in rabbit skin and the load of tuberculous bacteria in the liquefied substances, respectively. Methods: Rabbits were randomly divided into six groups: rIFN-gamma group, rIL-2 group, high-dose dexamethasone (DH) group, low-dose dexamethasone (DL) group, CTX group and normal saline control group. On the seventeenth day after the intervention of immunomodulators, the rabbit skin tuberculosis model was established by intradermal injection of 5 *106 CFU attenuated Mycobacterium bovis strain BCG into the abdomen and back of rabbits. The formation and development of skin tuberculosis nodules were observed dynamically during the continuous intervention. The morphology and size of granuloma, liquefaction, ulceration, healing time and nodules in each period were recorded, and the pathological morphology of skin nodules in each group was observed; the tuberculosis bacterial load in the liquefied substances of skin tuberculosis nodules in each group was counted; the serum cytokines IFN-gamma, IL-2.IL-4 in each group were detected by ELISA. IL-17 secretion level; comprehensive analysis of cytokine level on tuberculosis nodule formation and development and cytokine level and tuberculosis nodule liquefaction substance in the relationship between tuberculosis bacterial load.
Result:
1. The development and change of tuberculous nodules in skin of rabbits in each group are different. The specific manifestations are as follows: the development time of tuberculous nodules in each group is different (granuloma, liquefaction, ulceration, healing), and the volume and size of tuberculous nodules in each group are different in each period:
In the rIL-2 group, the nodules began to liquefy at the 8th day after BCG inoculation. The nodules began to liquefy at the earliest time. On the 11th day after BCG inoculation, the nodules broke and had two peaks of liquefaction. On the 13th day after BCG inoculation, the nodules reached the first liquefaction peak. The nodule volume in rIFN-gamma group was significantly larger than that in rIL-2 group (P 0.05).
The tuberculous nodule volume of low dose dexamethasone (DL) group was the smallest, and that of granuloma group was 751 (+ 153mm3), which was significantly smaller than that of control group (1699 (+ 149mm3) (P 0.05). The nodule volume of low dose dexamethasone (DL) group was (601 < 297) at liquefaction peak. Mm3 was also significantly lower than that of control group (2563
2. in the peak period of liquefaction of skin tuberculous nodules in different groups of rabbits, the amount of Mycobacterium tuberculosis in liquefied substances varied.
The load of tuberculosis bacteria in rIL-2 group was the lowest in each group. At the first liquefaction peak, the load of tuberculosis bacteria was 3.0 *106 CFU/g, which was significantly lower than that in control group (6.9x106 CFU/g). At the second liquefaction peak, the load of tuberculosis bacteria (1.7 *105CFU/g) was significantly lower than that at the first liquefaction peak. 07CFU/g) was significantly higher than that in the control group, the highest among all groups.
3. The levels of serum cytokines IFN-gamma, IL-2, IL-4 and IL-17 were different in different stages of tuberculous nodule development in each group.
The levels of serum IFN-gamma in granulomatous stage (1706.3+104.3 pg/ml) and peak liquefaction stage (2662.9+208.5 pg/ml) in gamma-IFN-gamma group were significantly higher than those before administration (866.2+29 pg/ml), and the peak liquefaction stage (2662.9+208.5 pg/ml) was higher than that in control group (964.9+51.7 pg/ml).
Serum levels of IL-2 in rIL-2 group and rIFN-2 group and rIFN-gamma group were at granuloma stage (rIL-2 group: 289.1 + 14.5 pg / ml; rIFN-gamma group: 211.1 + 17.6 pg / ml 1), liquefaction peak (rIL-2 group: 318 + 25.7 pg / ml; rIFN-gamgroup: 297.9 + 23.2 pg / m1) and healstage (rIL-2 group: 205.7 + 9.7 + 9.9.9 9 9 pg / ml; rIFN-gamgroup: 211.1 1 1 1 + 17.1 + 17.6 pg / ml), liquliquliquefpeak (rIL-2 group: 318 + 25.8 + 25.7 7 7.7 It was significantly higher than that of the water before administration in each group. The levels of serum levels in rIL-2 group (103.5+3.9 pg/ml) and rIFN-gamma group (79.2+2.0 pg/ml) were the highest (318+25.7 pg/ml in rIL-2 group and 297.9+23.2 pg/ml in rIFN-gamma group), which were higher than those in control group (201+5.9 pg/m1).
The level of IL-4 in the control group was significantly higher at the peak liquefaction stage (91.2+10.1 pg/m1) and the healing stage (87.7+3.1 pg/ml) than that before administration (50.6+0.5 pg/ml).
The serum levels of IL-17 in each group increased during the peak period of liquefaction, and the levels of IL-17 in rIFN-gamma group at the peak period of liquefaction (130.1+9.6 pg/ml) were significantly higher than those before administration (54.4+2.3 pg/ml).
4. Correlation analysis of cytokine level with tuberculosis nodule size and cytokine level with tuberculosis nodule liquefaction substance bacterial load showed that serum IL-2 level was positively correlated with tuberculosis nodule size (r2 = 0.748, P = 0.058), and was inversely correlated with tuberculosis bacterial load in liquefaction substance during liquefaction peak (r2 = 0.875, P = 0.020).
Conclusion:
1. Different immunomodulators have different effects on the formation and development of tuberculosis nodules, especially on the liquefaction and development of tuberculosis nodules, and on the survival of tuberculosis bacteria in the nodules.
2. Interleukin-2 significantly promotes the occurrence and development of tuberculosis lesion liquefaction, and promotes the decrease of tuberculosis bacteria load in the lesion. Dexamethasone inhibits the occurrence and development of tuberculosis lesion liquefaction, and is conducive to the survival of tuberculosis bacteria in the lesion.
3. a preliminary evaluation method for rabbit skin tuberculosis liquefaction model was established.
【學(xué)位授予單位】：蘭州大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2012
【分類號】：R392
【共引文獻(xiàn)】
相關(guān)期刊論文 前2條
1 韋_";張朝暉;曹芳;李緯;戴琨;范婧;;HPLC-ESI-MS聯(lián)用法測定大鼠血漿中KJY-01濃度及其藥動學(xué)研究[J];中國抗生素雜志;2011年06期
2 Naveen Kumar;Chandan Kumar Kedarishetty;Sachin Kumar;Vikas Khillan;Shiv Kumar Sarin;;Antitubercular therapy in patients with cirrhosis:Challenges and options[J];World Journal of Gastroenterology;2014年19期
相關(guān)會議論文 前1條
1 徐廣賢;趙德明;周向梅;尹曉敏;楊建民;;牛分枝桿菌mce4E蛋白對牛肺泡巨噬細(xì)胞iNOS、TNF-α、IL-6和IL-12表達(dá)的影響[A];中國畜牧獸醫(yī)學(xué)會獸醫(yī)病理學(xué)分會第十四次學(xué)術(shù)研討會、中國病理生理學(xué)會動物病理生理專業(yè)委員會第十三次學(xué)術(shù)研討會論文集[C];2006年
相關(guān)博士學(xué)位論文 前2條
1 劉平;基于ATP合成酶的新型抗結(jié)核化合物的設(shè)計(jì)、合成和生物活性評價(jià)[D];吉林大學(xué);2010年
2 尹曉敏;牛分枝桿菌Mb1514基因的原核表達(dá)及功能分析[D];中國農(nóng)業(yè)大學(xué);2013年
相關(guān)碩士學(xué)位論文 前1條
1 張瑞芹;結(jié)核分枝桿菌PPE37蛋白對RAW264.7巨噬細(xì)胞NF-κB、TNF-α、IL-6mRNA表達(dá)的影響[D];寧夏醫(yī)科大學(xué);2013年
，本文編號：2193625
本文鏈接：http://www.sikaile.net/xiyixuelunwen/2193625.html
最近更新
教材專著
